Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04395196

RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure

Although the adverse effects associated with prenatal alcohol exposure (PAE) are well known, many women continue to drink heavily during pregnancy, putting their infants at risk for fetal alcohol spectrum disorders. Animal studies have shown that choline supplementation can mitigate effects of PAE on growth and development. Choline, an essential nutrient, serves as a methyl-group donor for DNA methylation and is a constituent of the neurotransmitter acetylcholine and a precursor to major components of cell membranes. In an R21 feasibility trial, 70 heavy drinkers were randomly assigned to receive a daily dose of 2g of choline or a placebo from initiation of antenatal care to delivery in Cape Town, South Africa, where the incidence of heavy drinking during pregnancy and fetal alcohol syndrome are among the highest in the world. When compared with infants in the placebo arm, infants in the choline-treated arm were more likely to meet criterion for eyeblink conditioning, demonstrated markedly better recognition memory on the Fagan Test of Infant Intelligence, which is known to have predictive validity for school-age IQ, and had better postnatal gains in weight and head circumference. Key features of this study included the higher choline dose (4.4 times adequate intake (AI), compared to 1.7-2.5 in previous human studies) and initiation of treatment early in pregnancy. We are now conducting a fully-powered, double-blind, randomized, placebo-controlled choline supplementation trial in heavy drinking pregnant women from a rural community in South Africa (1) to assess the effectiveness of maternal choline supplementation during pregnancy to mitigate effects of PAE on three primary outcomes: infant recognition memory and postnatal growth restriction (weight and head circumference); (2) to assess the efficacy of this supplementation for mitigating alcohol effects on the following secondary outcomes: infant eyeblink conditioning, postnatal length, and information processing speed; (3) to use innovative methods in causal inference analysis to examine protocol adherence as an important source of variation in treatment efficacy and to identify sociodemographic factors associated with non-compliance in order to facilitate implementation of the intervention protocol in clinical settings; and (4) in exploratory analyses, to examine whether maternal choline supplementation is particularly effective in women with lower dietary choline intake or poor nutritional status.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

University of Cape Town Faculty of Health Sciences

Cape Town, Western Cape, 7925, South Africa

Location status: Recruiting

Location contact

Anthea Van Wyk

CONTACT

[email protected]

+27665643491

Ernesta Meintjes, PhD

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 yr
  • ≤20 wk gestation
  • Singleton pregnancy
  • Currently heavy drinking (average of ≥15 ml AA/day or binge drinking (≥4 standard drinks/occasion) on at least 1.5 occasions/month on average since becoming pregnant)
  • Current choline dietary intake <1 g/day
  • Language fluency in English or Afrikaans

Exclusion criteria

  • Use of methamphetamine or other illicit drugs other than marijuana during the past year
  • HIV positive
  • Pharmacologic treatment for a serious pre-existing medical condition (e.g., diabetes, hypertension, epilepsy, or cardiac problems)
  • Having another child enrolled in the trial from a previous pregnancy
  • Plans for mother or child to move away from the area prior to study completion

Treatment and study plan

Choline bitartrate

Dietary Supplement

Provided in beverage form

Placebo

Dietary Supplement

Provided in beverage form

Primary outcomes

  1. Infant recognition memory

    Time frame: 12 months

    Novelty preference from the Fagan Test of Infant Intelligence

  2. Postnatal infant weight gain

    Time frame: 6.5 months

  3. Postnatal growth in infant head circumference

    Time frame: 6.5 months

Secondary outcomes

  1. Infant information processing speed

    Time frame: 12 months

    Processing speed on the Fagan Test of Infant Intelligence

  2. Postnatal growth in infant length

    Time frame: 6.5 months

Study contacts

Contact information is provided by the study sponsor or research team.

R. Colin Carter, MD, MMSc

CONTACT

[email protected]

+16176949902

Sandra W Jacobson, PhD

CONTACT

[email protected]

+13139935454

Sponsors and collaborators

Lead sponsor

Wayne State University

Other

Collaborators

  • Columbia University
  • University of Cape Town

Registry information

Official study title

A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development

Important dates

Study start
2023
Primary completion
2027
Study completion
2028
First posted
May 20, 2020
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.